Postpartum diabetes risk was elevated among women with a history of gestational diabetes and a high-stable or inverse U-shaped BMI trajectory.

Lithium aspartate does not provide significant relief for post-COVID-19 symptoms of fatigue or cognitive dysfunction.

Using single maintenance and reliever therapy (SMART) is cost‐effective vs ICS/LABA maintenance plus SABA reliever in uncontrolled asthma.

Topline results were announced from a phase 3 trial evaluating SC pembrolizumab with berahyaluronidase alfa in metastatic NSCLC.

In IPF, antifibrotic therapy discontinuation was linked to patient variables that included depression, lower DLCO, and higher all-cause mortality.

Machine learning analysis of photo and video data demonstrates a promising way to noninvasively detect early hypertension and diabetes.

Global coverage with measles vaccination declined during the COVID-19 pandemic, and estimated measles cases increased 20 percent worldwide from 2022 to 2023.

Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Combat exposure was associated with a 12% increase in insomnia risk and 48% increase in sleep apnea risk among active-duty soldiers.

Povidone-iodine vs chlorohexidine gluconate demonstrated a reduction in deep SSI, but an increased risk for overall and superficial SSI.

Influenza-related hospitalization rates in the US varied significantly from 2010/2011 through the 2022/2023, an MMWR report found.